Loading
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Previous close
$1.735
+$0.415 · +31.44%
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Day range
Current $1.735
52-week range
Current $1.735
Historical prices · Market data may be delayed.
GoAI Score
Sell
Valuation
27
Expensive
Sentiment
33
Bearish
Risk
69
High Risk
Momentum
25
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Day range
Current $1.735
52-week range
Current $1.735
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2M USD | 11M USD | — | — | 250K USD |
| Cost of goods sold | 43.07M USD | 925K USD | 1.22M USD | 1.2M USD | 58.27M USD |
| Gross profit | −41.07M USD | 10.08M USD | −1.22M USD | −1.2M USD | −58.02M USD |
| Research and development | 43.57M USD | 63.1M USD | 103.73M USD | 79.35M USD | 58.27M USD |
| Selling, general, and administrative | 17.63M USD | 21.85M USD | 25.96M USD | 28.79M USD | 38.42M USD |
| Operating expenses | 18.23M USD | 84.02M USD | 128.47M USD | 106.94M USD | 38.42M USD |
| Interest income | 843K USD | 3.37M USD | 6.31M USD | 1.65M USD | 350K USD |
| Interest expense | — | — | — | — | 3K USD |
| Depreciation and amortization | 373K USD | 925K USD | 1.22M USD | 1.2M USD | 1.33M USD |
| Operating income | −59.31M USD | −73.94M USD | −129.69M USD | −108.14M USD | −96.44M USD |
| Net income | −59.61M USD | −69.78M USD | −123.46M USD | −105.28M USD | −95.4M USD |
Company facts updated Nov 13, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
